NEW YORK, May 30, 2019 /PRNewswire/ -- OTC
Markets Group Inc. (OTCQX: OTCM), operator of financial
markets for 10,000 U.S. and global securities, today announced
Cardiol Therapeutics Inc. (TSX: CRDL; OTCQX: CRTPF), a
biotechnology company, has qualified to trade on the OTCQX® Best
Market. Cardiol Therapeutics Inc. upgraded to OTCQX
from the Pink® market.
Cardiol Therapeutics Inc. begins trading today on OTCQX under
the symbol "CRTPF." U.S. investors can find current financial
disclosure and Real-Time Level 2 quotes for the company on
www.otcmarkets.com.
"We are pleased to welcome Cardiol Therapeutics to the OTCQX
Best Market," said Jason Paltrowitz,
EVP of Corporate Services at OTC Markets Group. "OTCQX companies
must meet high financial standards, demonstrate compliance with
U.S. securities laws, and have a professional third-party sponsor
introduction. Upgrading to the OTCQX Market from the Pink Market is
an important milestone for Canadian issuers, and we look forward to
supporting Cardiol Therapeutics as the company seeks to build
visibility in the US."
"Trading on the OTCQX Best Market will assist us with increasing
our U.S. shareholder base and investor awareness as we prepare to
launch our ultra-pure pharmaceutical CBD products in the billion
dollar market for medicinal cannabinoids in Canada and initiate ground-breaking
international clinical trials in heart disease later this year,"
said David Elsley, President and CEO of Cardiol
Therapeutics.
Dorsey & Whitney LLP acted as the company's OTCQX
sponsor.
About Cardiol Therapeutics Inc.
Cardiol Therapeutics
Inc. is a leader in the research and commercial development of
pharmaceutical CBD products and targeted therapies for inflammatory
disease. The Company is leveraging its expertise in pharmaceutical
CBD to develop ultra-pure CBD products for commercialization
in the billion dollar market for medicinal cannabinoids in
Canada, with a view to expanding
into Europe and Latin America, and nanotechnologies designed
to deliver cannabinoids and other anti-inflammatory drugs for the
treatment of heart failure. Heart failure is a leading cause of
death and hospitalization, with associated healthcare costs
exceeding $30 billion annually in the
U.S. alone. For further information about Cardiol, please visit the
Company's website at www.cardiolrx.com.
About OTC Markets Group Inc.
OTC Markets Group
Inc. (OTCQX: OTCM) operates the OTCQX® Best Market, the OTCQB®
Venture Market and the Pink® Open Market for 10,000 U.S. and global
securities. Through OTC Link® ATS and OTC Link ECN, we
connect a diverse network of broker-dealers that provide liquidity
and execution services. We enable investors to easily trade
through the broker of their choice and empower companies to improve
the quality of information available for investors.
To learn more about how we create better informed and more
efficient markets, visit www.otcmarkets.com.
OTC Link ATS and OTC Link ECN are SEC regulated ATSs, operated
by OTC Link LLC, member FINRA/SIPC.
Subscribe to the OTC Markets RSS Feed
Media Contact:
OTC Markets Group Inc., +1 (212)
896-4428, media@otcmarkets.com
View original
content:http://www.prnewswire.com/news-releases/otc-markets-group-welcomes-cardiol-therapeutics-inc-to-otcqx-300858500.html
SOURCE OTC Markets Group Inc.